Actithera is an early-stage radiotherapeutics company with a platform for the design of Theranostics with prolonged tumor retention and rapid peripheral clearance. Its approaches have been validated in its most advanced program that has reached a well differentiated Development Candidate. Actithera is actively fundraising for its Series A in order to grow the company, its pipeline and develop its first asset.